Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Hepatocellular 34 Carcinoma, Non-Small-Cell Lung 22 Melanoma 18 Squamous Cell Carcinoma of Head and Neck 16 Colorectal Neoplasms 15 Urinary Bladder Neoplasms 11 Lung Neoplasms 10 Liver Neoplasms 10 Breast Neoplasms 10 Biliary Tract Neoplasms 10 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Carcinoma, Renal Cell 9 Neoplasms 7 Cholangiocarcinoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Neoplasm Metastasis 5 Mesothelioma, Malignant 5 Fallopian Tube Neoplasms 5 Adenocarcinoma Of Esophagus 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Recurrence 3 Mesothelioma 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Endometrial Neoplasms 3

Interventions

lutetium Lu 177 dotatate 39 Everolimus 31 Magnetic Resonance Spectroscopy 15 lanreotide 13 gallium Ga 68 dotatate 12 Octreotide 12 Temozolomide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 9 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 pasireotide 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 copper dotatate CU-64 4 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡